The Ohio State University

ECPL

Experimental Cancer Pharmacology Laboratory (ECPL)

2024 Group picture

Within ECPL, members of the Baker, Hu, Sparreboom and Eisenmann lab actively collaborate on two themes within The Ohio State University College of Pharmacy’s Division of Pharmaceutics & Pharmacology: 1) cancer therapeutics, and 2) drug toxicity.

Mechanistic studies and preclinical investigations are undertaken to identify therapeutic strategies to circumvent clinical drug resistance and to mitigate chemotherapy-induced toxicity. Elucidation of mechanisms of drug-drug interactions, both intentional and unintentional, are integral to both areas of investigation. Our collaborative research leverages collective expertise in cancer pharmacology, preclinical models, transcriptomic/proteomic approaches, drug transporters, and pharmacokinetics with the goal of clinical translation to improve outcomes for cancer patients.

A diagram showing how the 4 different members of the ECPL interact with each other on projects while maintaining their own projects. The ECPL collaborates together on: Collaborations: Clinical pharmacology Preclinical models for ADME Technical expertise for PK/PD Transcriptomic/proteomic approaches Publications and grant funding Sparreboom lab specific projects include: OCT transporters - cancer drug interactions Preclinical models of drug transporters Mechanisms of transporter inhibition Baker specific projects include: Investigations in AML Developmental therapeutics Drug resistance Hu's lab specific projects include: OATP1B transporter - cancer drug interactions Chemo-induced peripheral neurotoxicity Biomarker identification Eisenmann's lab specific projects include: Neuropharmacology of Chemotherapy Impact of chemotherapy on the brain Role of SLC transporters in brain There is overlap between Sparreboom and Baker on transporter toxicity studies There is overlap between Sparreboom and Hu on regulation of transporters There is overlap between Hu and Eisenmann on peripheral neuropathy studies There is overlap between Eisenmann and Baker drug-drug interations